Evaluation of Plasma Modifications Associated With Rivaroxaban Treatment for Stroke Prevention in Patients With Atrial Fibrillation
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2016
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms Naco-Nimes
- 23 Aug 2016 Status changed from recruiting to completed.
- 03 Dec 2015 Planned End Date changed from 1 May 2017 to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 03 Dec 2015 Planned primary completion date changed from 1 May 2017 to 1 Jun 2016.